Nutra Pharma’s recently launched pain reliever adjudged as the Best New Product at ECRM Conference

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its recently launched pain reliever, Cobroxin, was selected as the “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference. Cobroxin was chosen as the award recipient by conference attendees, including several of the leading national retailers.

“Winning this award is an exciting achievement for Nutra Pharma, as it reflects the significant amount of positive response we have received from retailers who are looking to offer their customers a safe and effective alternative to current pain relievers,” commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma. “As we begin introducing Cobroxin through retailers this fall, we plan to continue our efforts educating both retailers and consumers about Cobroxin’s unique analgesic properties, which do not rely on opiates or acetaminophen for its pain relieving effects,” he concluded.

Cobroxin is the first OTC pain reliever clinically proven to treat Stage 2 (moderate to severe) chronic pain. The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray (NDC47219-102-52) for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel (NDC47219-104-50) for treating repetitive stress, arthritis, and joint pain.

Additional benefits to Cobroxin include:

• All Natural
• Non-Addictive
• Non-Narcotic
• Non-Opiate
• More Potent than Morphine
• Long Lasting

Recently, Nutra Pharma announced a licensing agreement that grants XenaCare Holdings (OTCBB: XCHO) ongoing exclusive marketing and distribution rights for Cobroxin within the United States in return for meeting specific minimum performance requirements. In addition, the Company also announced successful submission of final Cobroxin packaging and labeling to the Food and Drug Administration (FDA), the final step required to begin selling Cobroxin.

Resonant Medical To Exhibit Next Generation Clarity System At Europe's Pre-Eminent Radiation Oncology Conference

Resonant Medical, an innovator in soft tissue planning, image-guidance and adaptive radiotherapy products, today announced that the Company will be exhibiting the next generation of its multi-anatomy Clarity System at the 10th Biennial Meeting of The European Society of Therapeutic Radiology and Oncologists (ESTRO), being held in Maastricht, Netherlands.

Clarity provides cost effective soft tissue hybrid imaging, integrated within a singular point-of-care in the CT Suite. Clarity also provides structure based image-guided radiotherapy (IGRT) during daily radiation treatments. The next generation version of Clarity also supports adaptive radiotherapy by alerting physicians of changes in a target structure's precise location, shape and size and enabling them to use this information to adapt the patient's treatment plan as necessary. Additionally, the MAASTRO Clinic in Maastricht has begun offering the Clarity System for its prostate and breast treatments.

"We are honoured that the prestigious MAASTRO Clinic has adopted the Clarity System for clinical use in advanced planning and soft tissue based IGRT, thus expanding the availability of better patient care in Europe," said Tony Falco, founder and CEO of Resonant Medical. "Our continued momentum in the European market is further evidence that the radiation oncology community is recognizing the need to address the issue of tumor movement in soft tissue cancers, like breast cancer. As we unveil the latest generation of Clarity products at ESTRO, we hope to make the Clarity System available to an increasing number of cancer patients in Europe."

During the radiation treatment planning phase, Clarity allows physicians to automatically compare CT and 3D ultrasound images acquired at the same time with the patient in the same position, which can dramatically improve the treatment planning workflow when compared to CT alone. The Clarity System is based on daily auto-contouring and true 3D anatomy changes during the entire course of treatment, ensuring rapid and precise daily delivery to the intended target while sparing healthy tissue. Clarity's 3D ultrasound imaging is a gentle, non-invasive technology most often associated with pregnancy and providing images of babies. In addition to adding the Clarity System to treatment for breast and prostate cancer patients, physicians at MAASTRO will be exploring how the system may improve treatment planning and targeting in GYN, bladder and liver cancer patients.

"The MAASTRO Clinic is excited to offer this new application of 3D ultrasound technology that advances patient care by providing more accurate planning and guidance in the delivery of treatment to patients battling breast and prostate cancer," said Dr. Frank Verhaegen, Head of Physics at MAASTRO. "The Clarity System is radiation-free and with the information it provides physicians, patients can rest easier knowing that their radiation treatment can be delivered directly to the area where it is needed most. We are also excited about possible future collaborations with Resonant to develop additional applications of the Clarity System to continue addressing the issue of tumor movement in soft tissue cancers."

About the MAASTRO Clinic

MAASTRO Clinic (Maastricht Radiation Oncology Clinic) is a dedicated radiotherapy clinic, which has strategic agreements with the GROW research institute (School for Developmental Biology and Oncology), the Faculty of Health, Medicine and Life Sciences at Maastricht University and the University Hospital of Maastricht. MAASTRO Clinic offers state-of-the-art radiotherapy to more than 3500 cancer patients each year from the Limburg area in the Netherlands. One of the missions of MAASTRO Clinic is implementing and developing advanced imaging techniques for image-guided radiotherapy.

Source
Resonant Medical